ALX Oncology
Sophia Randolph MD PhD is the Chief Medical Officer at ALX Oncology. Previously, Sophia held positions at Pfizer as Executive Director in Oncology and at Merck Inc as Director Clinical Sciences/Oncology. With a background in Biochemistry, Cellular and Molecular Biology, and Internal Medicine/Medical Oncology, Sophia has led the clinical development and strategy for various oncology assets, including pioneering first in class molecules like IBRANCE and vorinostat. Throughout their career, Sophia has demonstrated expertise in trial development, translational medicine, and gene expression profiling strategies in early development clinical trials.
This person is not in any offices
ALX Oncology
ALX Oncology is a publicly traded, clinical-stage immuno-oncology company focused on helping patients fight cancer by developing therapies that block the CD47 checkpoint pathway and bridge the innate and adaptive immune system.